Skip to content

Author

M. Giuliano

We have 3 of 55 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · 0 citations
Review Open access Sep 2026

Multigene testing to guide clinical adjuvant decisions in breast cancer: An overview focused on the assessment of the quality of evidence with the grading of recommendations assessment, development and evaluation (GRADE) approach.

An appraisal of the clinical utility of genomic tests, particularly OncotypeDX®, aims to reinforce their fundamental role in personalizing adjuvant treatment decisions and optimizing resource allocation, while emphasizing the need for further research to address remaining uncertainties.

M. Dieci, P. Conte, D. Generali et al. · 0 citations
Review Open access Jul 2026

Unraveling the use of vaccine therapy in HER-2 positive breast cancer: a comprehensive review of current state and future perspectives

While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses.

A. Caltavituro, C. Martinelli, M. Palleschi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.